Growth differentiation factor 15: from stress response to clinical utility in chronic liver diseases.
The clinical landscape of chronic liver disease has changed with effective antiviral therapies, enabling the eradication of hepatitis C virus and the durable suppression of hepatitis B virus replicati
APA
Myojin Y, Hikita H (2026). Growth differentiation factor 15: from stress response to clinical utility in chronic liver diseases.. Journal of gastroenterology, 61(2), 117-130. https://doi.org/10.1007/s00535-025-02336-7
MLA
Myojin Y, et al.. "Growth differentiation factor 15: from stress response to clinical utility in chronic liver diseases.." Journal of gastroenterology, vol. 61, no. 2, 2026, pp. 117-130.
PMID
41432914
Abstract
The clinical landscape of chronic liver disease has changed with effective antiviral therapies, enabling the eradication of hepatitis C virus and the durable suppression of hepatitis B virus replication. Despite these advances, patients remain at risk for hepatocellular carcinoma (HCC) and other liver-related complications, but the growing burden of metabolic dysfunction-associated steatotic liver disease (MASLD) has created new challenges for clinical practice. These trends emphasize the need for reliable, noninvasive biomarkers that can stratify risk and guide long-term management across diverse etiologies. Growth differentiation factor 15 (GDF15), a stress-inducible cytokine, has attracted increasing interest as a promising biomarker. Its expression is induced by metabolic, oxidative, and inflammatory stress, and circulating levels increase with disease progression. Elevated serum GDF15 is consistently associated with fibrosis severity, HCC risk, hepatic decompensation, and mortality. Importantly, GDF15 is not merely a surrogate of fibrosis; rather, it integrates hepatocellular and stromal stress pathways and captures residual risk beyond fibrosis stage, liver function scores, and conventional biomarkers. In addition to its prognostic association, GDF15 has diverse biological effects. It may act as a protective response by limiting inflammation and cellular injury; yet, in other contexts, it contributes to fibrogenesis, tumor progression, immunosuppression, and cachexia. These dual roles highlight both the potential and the complexity of targeting GDF15 in therapeutic strategies. Collectively, the results of the current study indicate that GDF15 represents a promising biomarker in chronic hepatic diseases and is clinically independent of hepatic fibrosis. Further work is needed to clarify the underlying mechanisms, validate the prognostic utility, and determine whether GDF15 can be developed as a therapeutic target within precision medicine approaches.
MeSH Terms
Humans; Growth Differentiation Factor 15; Biomarkers; Carcinoma, Hepatocellular; Chronic Disease; Liver Diseases; Liver Neoplasms; Liver Cirrhosis; Disease Progression; Prognosis; Fatty Liver
같은 제1저자의 인용 많은 논문 (2)
- The effect of prior transarterial chemoembolization on response to immune checkpoint inhibitor treatment in patients with hepatocellular carcinoma.
- Serum Growth Differentiation Factor 15 Can Be a Novel Biomarker to Predict the Prognosis of Patients With Hepatitis C Virus Cirrhosis After Virus Elimination.